Head-to-head comparison
| Property | CagriSema | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~7 days (semaglutide component); cagrilintide ~7 days — both designed for weekly dosing | ~7 days |
| Mol. Weight | — | 4,113.58 Da |
| Side Effects | Nausea (very common, typically transient), Vomiting, Diarrhea | Nausea (39%), Vomiting, Diarrhea |
Key differences
- Mechanism: Semaglutide activates GLP-1 receptors only; CagriSema adds cagrilintide-mediated amylin receptor activation in the area postrema and nucleus tractus solitarius for additive appetite suppression through both hedonic and homeostatic pathways.
- Evidence: Semaglutide has six completed STEP trials with over 10,000 participants and FDA approval; CagriSema has Phase 3 REDEFINE data but is not yet approved by any Western regulatory agency.
- Efficacy: STEP trials showed 15-17% mean weight loss over 68 weeks with semaglutide 2.4 mg; REDEFINE 1 showed 20.4% mean weight loss with CagriSema over the same 68-week period.
- Side effects: Semaglutide causes nausea in approximately 39% of patients; CagriSema reported GI adverse events in 79.6% of participants versus 39.9% on placebo, though most were transient and mild to moderate.
- Dosing: Both are once-weekly subcutaneous injections. Semaglutide titrates from 0.25 mg to 2.4 mg over ~16 weeks; CagriSema titrates both components to 2.4 mg each over 16-20 weeks.
- Legal status: Semaglutide is FDA-approved as a prescription medication (Ozempic, Wegovy); CagriSema remains investigational with no FDA or EMA approval as of 2026.
- Cost and access: Semaglutide is commercially available though supply-constrained; CagriSema is available only through clinical trials.
The verdict
Semaglutide is the established standard with broad regulatory approval, extensive real-world data, and proven cardiovascular outcomes. CagriSema demonstrates meaningfully greater weight loss in Phase 3 trials by engaging a second appetite pathway, but it carries higher GI side-effect rates and remains investigational. The choice is effectively between a proven monotherapy and a potentially superior combination that has not yet cleared regulatory review.
Frequently asked questions
CagriSema adds cagrilintide, a long-acting amylin analogue, to the semaglutide GLP-1 component. Amylin acts on area postrema and brainstem satiety centers through pathways that are complementary to and partially independent of GLP-1 signaling. This dual-pathway activation produces additive appetite suppression that exceeds what either agent achieves alone.
No. As of 2026, CagriSema is not approved by the FDA or EMA. Novo Nordisk has completed the Phase 3 REDEFINE program and is pursuing regulatory submission. Semaglutide, its GLP-1 component, is separately FDA-approved as Ozempic and Wegovy.
REDEFINE trials reported GI adverse events in 79.6% of CagriSema patients versus roughly 39% nausea rate for semaglutide in STEP trials. However, most CagriSema GI events were transient and mild to moderate. The higher rate likely reflects the additive GI burden of amylin-pathway activation on top of GLP-1 effects.
CagriSema is not commercially available and can only be accessed through clinical trials. A switch from semaglutide to CagriSema would require enrollment in an authorized study. Semaglutide is one of the two active components in CagriSema, so patients already on semaglutide would be adding the cagrilintide amylin component.
In Phase 3 trials, CagriSema produced 20.4% mean body weight loss over 68 weeks (REDEFINE 1), compared to 15-17% with semaglutide 2.4 mg over the same duration (STEP trials). Approximately 60% of CagriSema participants lost at least 20% of body weight, and 23% lost 30% or more.